GC
iKang shrugs off China weakness to price healthy IPO
Beijing-based iKang Healthcare Group priced its $153m Nasdaq listing at the top of the range this week, as investors jumped at the chance to gain exposure to one of the fastest growing industries in China.
The deal priced on April 8 in the US, at $14 per share, the top of a $12-$14 range. The transaction comprised 10.9m American Depositary Shares — with every two ADSs representing one of iKang’s ordinary shares.
“It was a very good final book, highly oversubscribed, with more ...Already a subscriber? Login
Further reading
-
Corp
Vedanta builds war chest for corporate revamp
-
FIG
CDB Leasing takes tight pricing approach, meets goals
-
Corp
Fantasia, Sunac find demand for new bonds
-
Regulation & Policy
China policy and markets round-up: Beijing hones in on green finance, southbound Bond Connect to launch before year-end, BOC, ICBC name new presidents
